logo
CanyamAI summaries for academic research
language
MobileMobile
  • Phone FeatureWeChat Mini Program
EnglishEnglish
noticeNotice
BlogBlog
delete
arrow
Back
J

Julio Rosenstock

University of Texas Southwestern Medical Center

120H-index
694Paper Count
6.6WCitation Count
Published Papers 356
Publication Date
logo
Potential Mediators of Efpeglenatide's Cardiovascular Benefit: An Exploratory Analysis of the AMPLITUDE-O Trial
errDIABETES OBESITY & METABOLISM
IF5.7
err2026-08-05
err0
errOAAI
errDaniel Raaschou-Oddershede; Christine R. Schwarz; Tanya Kovalova; Kelley R. Branch; Stefano Del Prato; Carolyn S. P. Lam; Renato D. Lopes; Richard Pratley; Julio Rosenstock; Naveed Sattar
errShare
errSave
Impact of Simultaneous Initiation of Finerenone and Empagliflozin on Albuminuria Irrespective of Baseline HbA1c Levels: A Participant-Level Exploratory Analysis of the Randomised CONFIDENCE Trial
errDIABETES OBESITY & METABOLISM
IF5.7
err2026-08-05
err0
errOAAI
errJanet B. McGill; Jennifer B. Green; Hiddo J. L. Heerspink; Johannes F. E. Mann; Amy K. Mottl; Julio Rosenstock; Peter Rossing; Muthiah Vaduganathan; Masaomi Nangaku; Meike Brinker; Charlie Scott; Katja Rohwedder; Li Li; Na Li; Margarida Seco; Rajiv Agarwal
errShare
errSave
Publisher Correction: Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial
errNature Medicine
IF50
err2026-06-24
err0
errOAAI
errJulio Rosenstock; Ildiko Lingvay; Donna Ryan; Ania M. Jastreboff; Robert Kushner; Andres Acosta; Thomas C. Blevins; Melissa Choi; Faith L. Holmes; Timothy Smith; Lisa Connery; Yao Li; Mike Ke Liu; Aline Barth; Jamie Butcher; Antonio Civitarese; Huibin Yue; Blai Coll
errShare
errSave
Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial
errNature Medicine
IF50
err2026-06-05
err0
errOAAI
errJulio Rosenstock; Ildiko Lingvay; Donna Ryan; Ania M. Jastreboff; Robert Kushner; Andres Acosta; Thomas C. Blevins; Melissa Choi; Faith L. Holmes; Timothy Smith; Lisa Connery; Yao Li; Mike Ke Liu; Aline Barth; Jamie Butcher; Antonio Civitarese; Huibin Yue; Blai Coll
errShare
errSave
Simplified Switching to Once-Weekly Insulin Icodec Without an Initial One-Time Additional Dose Versus Once-Daily Insulin Glargine U100 in Basal Insulin-Treated Type 2 Diabetes (ONWARDS 10): A Randomised Controlled Trial
errdiabetes, obesity and metabolism
IF0
err2026-05-21
err0
errOAAI
errJulio Rosenstock; Chantal Mathieu; Joshua Buron Feinberg; Priyanka Rao; Cathrine Scavenius; Alice Y. Y. Cheng
errShare
errSave
Glycaemic Control According to the Final Insulin Dose Using an Innovative Fixed-Dose Titration of Weekly Insulin Efsitora in Insulin-Naïve Type 2 Diabetes
errdiabetes, obesity and metabolism
IF0
err2026-05-03
err0
errOAAI
errLisa Connery; Julio Rosenstock; Neda Rasouli; Alice Y. Y. Cheng; Andreas Liebl; Qianqian Wang; Vitoria Pires; Alastair Knights; Michael B. Davidson; Christopher J. Child
errShare
errSave
Sexual dimorphism and age effects in CKD and type 2 diabetes in the CONFIDENCE trial
errNephrology Dialysis Transplantation
IF5.6
err2026-04-01
err0
PREAI
errAgarwal, Rajiv; Green, Jennifer B.; Heerspink, Hiddo J. L.; Mann, Johannes F. E.; McGill, Janet B.; Mottl, Amy K.; Nangaku, Masaomi; Rosenstock, Julio; Vaduganathan, Muthiah; Scott, Charlie; Li, Li; Li, Na; Aldworth, Carolina; Brinker, Meike; Rossing, Peter
errShare
errSave
Risk of Hyperkalemia With Empagliflozin, Finerenone, or Both: Secondary Analysis of CONFIDENCE Randomized Trial
errJACC
IF0
err2025-11-07
err0
errOAAI
errRajiv Agarwal; Jennifer B. Green; Hiddo J.L. Heerspink; Janet B. McGill; Amy Mottl; Masaomi Nangaku; Julio Rosenstock; Peter Rossing; Muthiah Vaduganathan; Carolina Solis-Herrera; Charlie Scott; Li Li; Meike Brinke; Carolina Aldworth; Johannes F.E. Mann
errShare
errSave
Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both Post Hoc Analyses of CONFIDENCE Trial
errJOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
IF9.4
err2025-11-01
err0
PREAI
errMottl, Amy; Scott, Charlie; Green, Jennifer B.; Heerspink, Hiddo J. L.; Mann, Johannes F. E.; Mcgill, Janet B.; Nangaku, Masaomi; Rosenstock, Julio; Rossing, Peter; Li, Li; Li, Na; Vaduganathan, Muthiah; Agarwal, Rajiv
errShare
errSave
Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial
errThe Lancet Diabetes & Endocrinology
IF0
err2025-09-14
err0
PREAI
errSean Wharton; Paula Freitas; Jøran Hjelmesæth; Maria Kabisch; Kristian Kandler; Ildiko Lingvay; Maria Quiroga; Julio Rosenstock; W Timothy Garvey
errShare
errSave
Once-weekly semaglutide 7·2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial
errThe Lancet Diabetes & Endocrinology
IF0
err2025-09-14
err0
PREAI
errIldiko Lingvay; Sara J Bergenheim; John B Buse; Paula Freitas; W Timothy Garvey; Nina M Harder-Lauridsen; Julio Rosenstock; Kushal Sahu; Sean Wharton
errShare
errSave
Impact of Simultaneous Initiation of Finerenone and Empagliflozin on Urinary Albumin-to-Creatinine Ratio in Asia. Pre-Specified Analysis of CONFIDENCE
errCLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
IF7.1
err2025-09-01
err2
errOAAI
errAgarwal, Rajiv; Green, Jennifer B.; Heerspink, Hiddo J. L.; Mann, Johannes F. E.; Mcgill, Janet B.; Mottl, Amy; Osonoi, Takeshi; Pal, Atanu; Rossing, Peter; Rosenstock, Julio; Vaduganathan, Muthiah; Li, Li; Li, Na; Scott, Charlie; Manjrekar, Pravin; Yamashita, Satoshi; Nangaku, Masaomi
errShare
errSave
Orforglipron, an oral non-peptide glucagon-like peptide-1 receptor agonist, improves markers of β-cell function and insulin sensitivity in type 2 diabetes
errdiabetes obesity metabolism
IF0
err2025-08-14
err0
PREAI
errJulio Rosenstock MD; Deborah A. Robins MS; Kevin L. Duffin PhD; Jonathan M. Wilson PhD; Yanzhu Lin PhD; Hiya Banerjee PhD; Sarah Eyde PhD; Christof Kazda MD; Manige Konig MD; Kieren J. Mather MD
errShare
errSave
Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial
errNephrology Dialysis Transplantation
IF5.6
err2025-08-01
err0
errOAAI
errVaduganathan, Muthiah; Green, Jennifer B.; Heerspink, Hiddo J. L.; Kim, Sung Gyun; Mann, Johannes F. E.; McGill, Janet B.; Mottl, Amy; Nangaku, Masaomi; Rosenstock, Julio; Rossing, Peter; Li, Li; Li, Na; Rohwedder, Katja; Scott, Charlie; Agarwal, Rajiv
errShare
errSave
Health status in stage B heart failure from diabetic cardiomyopathy baseline results from ARISE-HF
errJOURNAL OF DIABETES AND ITS COMPLICATIONS
IF3.1
err2025-07-01
err0
PREAI
errSiddiqi, Tariq Jamal; Liu, Yuxi; Zannad, Faiez; Tang, W. H. Wilson; Solomon, Scott; Rosenstock, Julio; Perfetti, Riccardo; Marwick, Thomas H.; Lewis, Gregory D.; Lam, Carolyn S. P.; Ibrahim, Nasrien E.; Ezekowitz, Justin; Del Prato, Stefano; Butler, Javed
errShare
errSave
Sex Differences in Diabetic Cardiomyopathy and Treatment Response to AT-001
errjacc heart failure
IF0
err2025-05-08
err0
errOAAI
errVanessa Blumer; James L. Januzzi; Yuxi Liu; Javed Butler; Justin A. Ezekowitz; Riccardo Perfetti; Julio Rosenstock; Stefano Del Prato; W.H. Wilson Tang; Alessia Urbinati; Faiez Zannad; Gregory D. Lewis; Scott D. Solomon; Sheila Hedge; Nasrien E. Ibrahim; Carolyn S.P. Lam
errShare
errSave
Time spent in glycaemic control with sustained body weight reduction with tirzepatide: A post hoc analysis of the SURPASS clinical trial programme
errDIABETES OBESITY & METABOLISM
IF5.7
err2025-03-01
err0
PREAI
errBergman, Brandon K.; Rosenstock, Julio; Garvey, W. Timothy; Batterham, Rachel L.; Chen, Yanyun; Liu, Minzhi; Sharma, Palash; Karanikas, Chrisanthi A.; Thieu, Vivian T.
errShare
errSave
Echocardiographic phenotypes of diabetic myocardial disorder: evolution over 15 months follow-up in the ARISE-HF trial
errCARDIOVASCULAR DIABETOLOGY
IF10.6
err2025-01-13
err1
errOAAI
errMarwick, Thomas H.; Lam, Carolyn; Liu, Yuxi; Del Prato, Stefano; Rosenstock, Julio; Butler, Javed; Ezekowitz, Justin; Ibrahim, Nasrien E.; Tang, W. H. Wilson; Zannad, Faiez; Perfetti, Riccardo; Januzzi, James L.
errShare
errSave
Impact of baseline FIB-4 score on efpeglenatide benefits on cardiovascular outcomes in people with type 2 diabetes: a participant-level exploratory analysis of the AMPLITUDE-O trial
errCARDIOVASCULAR DIABETOLOGY
IF10.6
err2024-09-28
err0
errOAAI
errDel Prato, Stefano; Li, Zhuoru; Ramasundarahettige, Chinthanie; Branch, Kelley R. H.; Lam, Carolyn S. P.; Lopes, Renato D.; Pratley, Richard; Rosenstock, Julio; Sattar, Naveed; Gerstein, Hertzel C.
errShare
errSave
Do nonglycaemic effects such as weight loss account for HbA1c lowering with efpeglenatide?: Insights from the AMPLITUDE-O trial
errDIABETES OBESITY & METABOLISM
IF5.7
err2024-09-16
err0
errOAAI
errGerstein, Hertzel C.; Yang, Mu; Lee, Shun Fu; Branch, Kelley R. H.; Del Prato, Stefano; Lam, Carolyn S. P.; Lopes, Renato D.; Pratley, Richard; Rosenstock, Julio; Sattar, Naveed
errShare
errSave

Research Directions

No research directions
Co-authors
Cooperation Journals
N
Naveed Sattar
H-index: 204 · Papers: 2.2K
G
Gregg C. Fonarow
H-index: 198 · Papers: 3.0K
S
Stuart Pocock
H-index: 166 · Papers: 952
K
Kamlesh Khunti
H-index: 162 · Papers: 2.1K
S
Stephen S. Rich
H-index: 160 · Papers: 1.9K
View more